DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
(S)-3,5-DHPG (HB0045)
Description:Selective group I mGlu receptor agonist. Induces LTD.
Purity:>99%
-
-
Dihydroergocristine mesylate (HB1611)
Description:5-HT antagonist. Also partial agonist at adrenergic and dopaminergic receptors.
Purity:>98%
-
Dihydroergotamine mesylate (HB1612)
Description:Partial α-adrenergic agonist, partial D2 agonist and 5-HT antagonist
Purity:>98%
-
-
L-DOPA methyl ester hydrochloride (HB5354)
Description:Water soluble L-DOPA derivative
Purity:>98%
-
- Description:
Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator. Brain penetrant. Water soluble.
Purity:>98%
-
DREADD agonist 21 (Compound 21) (HB4888)
Description:Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator. Brain penetrant.
Purity:>98%
